SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to a significant price drop, sparking intense debate among investors regarding potential insider selling after a lock-up period expired. The community is actively analyzing trading volume and support levels, with some viewing the dip as a buying opportunity, while others express concern about continued selling pressure. Amidst the volatility, there's speculation about a potential short squeeze and comparisons to similar situations with other trading platforms.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions of a potential bubble in the quantum computing sector and scrutiny of its high valuation relative to revenue. Community chatter includes debate between bullish and bearish viewpoints, with some highlighting insider selling and concerns about future dilution, while others remain optimistic about the long-term potential of quantum computing. Technical analysis and pattern observations are also prominent in the conversation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate whether the stock is overvalued and due for a pullback, or if it still has room to run based on the future potential of quantum computing. Bears cite concerns over financials and potential offerings, while bulls point to the company's advancements and growing interest in the sector. Discussions also involve comparing RGTI to other quantum computing stocks and broader market trends.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors react to news of a significant deal with OpenAI, including OpenAI potentially acquiring a substantial stake in AMD. The community buzz centers on the implications of this partnership for AMD's position in the AI chip market, with some anticipating significant growth and others cautioning about overvaluation. Bullish sentiment is strong, with many seeing AMD as a key player in the future of AI.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amidst community discussion around a recent private placement and its potential impact, with debates focusing on dilution versus the company's increased financial strength. Some traders are pointing to technical indicators and anticipating a short squeeze, while others express concerns about the company's fundamentals and an ongoing SEC investigation; the stock's movement is also discussed in the context of the broader quantum computing sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending amid fluctuating sentiments, with community members debating whether it's experiencing a classic panic sell-off or a bear trap. Some traders are suggesting taking profits, while others urge holding for a potential surge, emphasizing the company's long-term prospects in the quantum computing sector. The conversation includes discussion of a newly launched ETF that shorts QBTS.

Fitell Corp. engages in the business of selling gym and fitness equipment. It also offers turnkey solution for personal training studios and commercial gym chains. Its brands include Muscle Motion, Rapid Motion, and FleetX. The company was founded in 2007 and is headquartered in Sydney, Australia.

Fitell Corp - Ordinary Shares - Class A

Fitell Corp

FTEL is trending due to high volume and community discussion around its low float and potential for a significant price increase. The company's recent investment in a Solana treasury and Nasdaq extension are being viewed as positive catalysts. Community members are actively discussing potential price targets and the possibility of a short squeeze.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its potential for a short squeeze, driven by high short interest and unusual options activity. Some investors are optimistic about the company's AI-driven drug discovery platform, particularly its use case in healthcare, and potential catalysts. Others remain cautious, pointing to insider selling and cash burn as concerns.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

American Rebel Holdings is trending due to an announced 1-for-20 reverse stock split with a unique "round lot protection" provision guaranteeing those holding at least 100 shares will maintain that amount post-split, sparking community debate and speculative trading strategies. Traders are actively discussing the potential for a short squeeze and the stock's volatile history, while also evaluating the implications of insider selling and a recent resolution of debt with Bank of America. The community is weighing the risks and potential rewards of this situation.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending as community members discuss the potential impact of the company's focus on building a TON token treasury and its integration with the Telegram ecosystem. Some traders are drawing comparisons to other recent low-float runners and anticipating a significant price movement. However, other investors caution about potential dilution and the company's shift in focus from biotech to crypto.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics jumped to the top of Stocktwits’ trending tickers after a burst of weekend retail chatter tied to deal speculation, rotation flows out of Eli Lilly, and near-term trial milestones.&nbsp;The stock traded nearly 4% higher in overnight trade on Sunday, while retail sentiment was ‘bullish’ amid ‘normal’ message volume.Users pointed to profit-taking in large caps and rotation into Viking, floated the idea of a potential approach from Lilly, and argued that shares are being re-rated since Metsera’s buyout&nbsp;by Pfizer created a perceived price floor for peers.Several&nbsp;watchers on Stocktwits highlighted the company’s next catalyst path. Interest centered on the planned subcutaneous-to-oral maintenance study, which CEO Brian Lian said on a Bernstein call is slated to begin “late this quarter or early next quarter.”&nbsp;Some saw intrigue in the design and flagged a possible “sell-the-news” setup, while others anticipated updates on spend and Phase 3 enrollment on the upcoming earnings call and kept partnership or buyout scenarios “in play.”<stembedurl>https://stocktwits.com/saifnila2/message/631119435</stembedurl><stembedurl>https://stocktwits.com/saifnila2/message/631074611</stembedurl>Last month,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/viking-therapeutics-stock-boost-pfizer-metsera-deal-btig-retail-slams-rivals-inferior-pipelines/chDhieAR3P5">BTIG suggested that Viking is benefiting from Pfizer’s agreement</a> to acquire Metsera, which expands Big Pharma's appetite for cardiometabolic assets. The research firm reiterated its ‘Buy’ rating with a $125 target, citing sharpened strategic optionality following recent M&amp;A, while Roche’s takeover of 89bio reinforced expectations for continued deal activity across the obesity and NASH pipelines.Retail voices remained split on strategy. Some argued Viking should not “go it alone,” given its lean headcount and would be better served by a larger commercial partner. Others framed the setup more broadly, citing pipeline breadth, potential rate-cut tailwinds, patent positioning, and a “David vs Goliath” narrative that could keep both institutions and retail engaged.<stembedurl>https://stocktwits.com/Reaperofmars1/message/631069156</stembedurl><stembedurl>https://stocktwits.com/LastResort/message/631074413</stembedurl>Investors also revisited&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/viking-short-interest-hits-5-year-high-after-weight-loss-drug-stumble/chss46sRdKN">the August data on oral VK2735</a>, noting a double-digit mean weight loss at 13 weeks, with tolerability viewed as manageable,&nbsp;although not as pristine as in the early studies.&nbsp;Several analysts, including B. Riley, Leerink, Jefferies, Stifel, and JPMorgan, called the selloff that followed overdone, emphasizing dose flexibility, maintenance positioning, and the potential to modulate gastrointestinal events through slower titration.<a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 26% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts 

Shares rose nearly 4% overnight as investors tied Viking’s upcoming trial and its positioning to renewed obesity-drug deal momentum after Pfizer’s Metsera buyout.

Equity

Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.

Can NVO Maintain Obesity Leadership With Next-Generation Candidates?

Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?

Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $24.97, denoting a -4.88% move from the preceding trading day.

Shares of Viking Therapeutics rose 3.4% to $26.25 on Monday and extended gains after hours,&nbsp;with a Wall Street research firm suggesting the biopharma is benefiting from Pfizer’s buyout offer for Metsera as it looks to bolster its obesity drug pipeline.BTIG reiterated a ‘Buy’ rating and $125 price target on&nbsp;Viking’s stock, saying the transaction sharpens&nbsp;the company’s&nbsp;clinical updates and strategic optionality while bolstering sentiment ahead of key readouts. The commentary followed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/89bio-stock-surges-roche-3-5b-buyout-wall-street-analyst-cautious/chDdNVaR3br">Roche’s acquisition of 89bio</a>, signaling increased deal activity in the biotech space.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> surged to an all-time high Monday, marking their biggest one-day gain ever.&nbsp;As part of the deal, Pfizer will pay Metsera $47.50 in cash per share, giving the company an enterprise value of $4.9 billion. If three clinical milestones are achieved, additional payments of $22.50 per Metsera share will be made, bringing the total value of the deal to as much as $7.3 billion. The deal is expected to close in the fourth quarter of 2025, pending approvals.Metsera, a clinical-stage biotech developing therapies for obesity and cardiometabolic diseases, will add four differentiated programs to Pfizer's pipeline. The assets include weekly and monthly injectable GLP-1 receptor agonists, two orally delivered GLP-1 candidates, and MET-233i, a monthly injectable amylin analog. The company previously discontinued its own obesity candidate Danuglipron.Viking was also in the spotlight, with Daniel Newman, CEO of Futurum Equities,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/1970178447411683535">posting on X</a> that Viking’s valuation “just got a massive shot in the arm with the Pfizer deal to buy Metsera,” describing Metsera’s GLP-1 program as “a far less exciting GLP” and arguing that Viking is “worth far more than $7.2 billion.”On Stocktwits, retail sentiment was ‘extremely bullish’ for both Pfizer and Metsera amid ‘extremely high’ message volume, while Viking drew ‘bullish’ sentiment alongside ‘high’ activity.One bullish user said Viking management had likely rejected lowball offers from large pharma, leaving rivals to acquire ‘inferior pipelines.<stembedurl>https://stocktwits.com/deerhtide/message/629602680</stembedurl>Another pointed to debate over whether Viking should pursue a buyout or go-it-alone strategy, adding that CEO Brian Lian’s stake of more than two million shares aligns him with investors. The user disclosed holding 83,000 shares, calling the position conviction-driven.<stembedurl>https://stocktwits.com/SauceMan912/message/629604221</stembedurl>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> is down 4.5%, Metsera’s shares have more than doubled, and&nbsp;<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics’ stock</a> has fallen 34.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?

NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$33.46
Prev Close	$31.54
Open	$31.94
Dividend Yield	0.00%
50-Day Moving Average	$29.37
Beta	1.34
Avg. Volume	5.26M
PE Ratio	-20.55

52-Week High	$81.73
52-Week Low	$18.92
Market Capitalization	$3.55B
EPS (Annual)	-$1.01
Price to Book	4.45
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VKTX News

VKTX Viking Therapeutics Inc